Jan Kaiserle

The landscape of biopharmaceutical research and development (R&D) has seen a remarkable evolution, particularly in the realm of oncology. In recent years, a significant portion of R&D investments has been channeled into cancer research, paving the way for groundbreaking treatments and

In a significant move reflecting the growing regulatory pressure on data security practices, Enzo Biochem has reached a settlement with the Attorneys General of Connecticut, New York, and New Jersey over allegations of inadequate security measures leading to a data breach earlier this year. The

Bora Pharmaceuticals continues its robust expansion by acquiring a significant operational stake in Tanvex BioPharma, a deal set to close in early 2025. This strategic acquisition positions Bora as the largest shareholder in Tanvex, granting the company access to a commercial-scale production

U.S. lawmakers are raising alarms about clinical trials conducted in China, specifically those affiliated with the Chinese military or located in the Xinjiang Uyghur Autonomous Region. This heightened vigilance is poised to dramatically impact how the U.S. FDA scrutinizes data from these trials.

Recent research breakthroughs have revealed an intriguing and unexpected benefit of certain cancer drugs: the potential to protect against Alzheimer's disease. Originally developed for combating cancer, these medications have shown promise in preventing Alzheimer's in animal models such

MSD, also known as Merck in North America, has taken a significant step to enhance its therapeutic portfolio by investing $1.3 billion in the acquisition of CN201 from Curon Biopharmaceutical. The investigational bispecific antibody is poised to change the landscape of treatments for B-cell

The journey from a new chemical entity (NCE) to a marketable drug product is a complex, multifaceted process that demands an intricate blend of scientific expertise and practical knowledge. The transformation involves a deep understanding of organic chemistry, analytical development, pharmaceutical

Clinical trials are the bedrock upon which medical advancements are discovered and validated. However, the traditional processes involved in clinical trials are fraught with inefficiencies, high costs, and prolonged durations that hinder timely medical innovations. Ushur, a leader in AI-powered

The biopharma sector is at an inflection point as the United States grapples with concerns about China's influence and potential risks posed by collaborations with Chinese military medical institutions. A legislative measure known as the BIOSECURE Act aims to address these apprehensions,

Tanvex BioPharma USA, Inc., a frontrunner in biologics development, has made significant strides by securing FDA approval for NYPOZI (filgrastim-txid) and advancing its Biologics License Application (BLA) for TX-05. These milestones underscore the company’s unwavering commitment to delivering h